01 May 2004
Safety and tolerability of the combination therapy with pegylatedinterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in patientswith chronic hepatitis C in Poland – interim analysis of data fromEAP program
Marta Wawrzynowicz-Syczewska, Marek Wasilewski, Hanna Trocha, Ewa Topczewska-Staubach, Krzysztof Tomasiewicz, Katarzyna Świętek, Katarzyna Szamotulska, Katarzyna Sikorska, Andrzej Horban, Marek Beniowski, Hanna Berak, Beata Bolewska, Anna Boroń-Kaczmarska, Janusz Cianciara, Andrzej Cieśla, Jacek Gąsiorowski, Andrzej Gietka, Ewa Gliwińska, Andrzej Gładysz, Zbigniew Gonciarz, Waldemar Halota, Małgorzata Inglot, Urszula Janas-Skulina, Ewa Janczewska-Kazek, Jolanta Jaskowska, Krzysztof Jurczyk, Jacek Juszczyk, Brygida Knysz, Wiesław Kryczka, Jan Kuydowicz, Anna Lakomy, Beata Logiewa-Bazger, Małgorzata Zejc-Bajsarowicz, Dorota Zarębska-Michaluk, Witold Wrodycki, Anna Łyczak, Tomasz Mach, Włodzimierz Mazur, Zofia Michalska, Roma Modrzewska, Khalil Nazzal, Paweł Pabjan, Anna Piekarska, Paweł PiszkoMed Sci Monit 2004; 10(1): 12-16 :: ID: 11832
Abstract
Open-label, multicenter extended availability program with peginterferon alfa-2a used in combination with ribavirin in patients with CHC in Poland was analysed. Finally, 572 patients were enrolled. The interim analysis of safety and tolerability was performed in 190 patients whose data were available after 72 weeks of observation. Mean hemoglobin level was 14.8 g/dl and decreased to week 24, then remain stable until the end of therapy and returned to the baseline value. Lekocytes level in week 2 decreased, reach a plateau in week 8 and return to baseline values at end observation. Similar phenomenon was observed with neutrophils. Platelet count during the treatment fell gradually in week 8 and remained stable. Reported adverse events requiring PEGASYS® or COPEGUS
® dose reduction were also analyzed. The most frequent adverse effect leading to the reduction of peginterferon alfa-2a dose was reduction. It was noted in 16 patients out of 18, who had the doses reduced because of adverse effects. Only in 5 patients, the dose was reduced because of depression or anxiety. Combined therapy was generally well-tolerated, preliminary analysis data confirms similar tolerability profile to that observed in phase III clinical trials.
Keywords: combination therapy with pegylated interferon alfa-2a and ribavirin, safety and tolerability, chronic hepatitis C
1021 4
Editorial
01 November 2023 : Editorial
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is DeclaredDOI: 10.12659/MSM.942960
Med Sci Monit 2023; 29:e942960
In Press
28 Nov 2023 : Clinical Research
Impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical Research
Long-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...Med Sci Monit In Press; DOI: 10.12659/MSM.943031
27 Nov 2023 : Clinical Research
Comparison of Outcomes from Emergency Admissions to a Major Trauma Center in Turkey of 1646 Elderly Patient...Med Sci Monit In Press; DOI: 10.12659/MSM.942916
27 Nov 2023 : Clinical Research
Evaluating Modified Ultrasound-Guided Serratus Anterior Plane Block for Enhanced Postoperative Recovery in ...Med Sci Monit In Press; DOI: 10.12659/MSM.942757
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292